Top in hem/onc: Rise in HPV-associated cancers, American Cancer Society’s first female CEO
New data revealed a decline in cervical cancer but an increase in other HPV-associated cancers over the past 2 decades in the United States. The findings were presented at the virtual ASCO Annual Meeting.
This was the top story in hematology/oncology last week.
Another top story was a Q&A with Karen E. Knudsen, PhD, MBA, the incoming CEO of the American Cancer Society and its Action Network. Knudsen is the first women to serve in this role.
Read these and more top stories in hematology/oncology below:
Cervical cancer incidence declines as rates of other HPV-associated cancers rise
Incidence of cervical cancer declined as rates of other HPV-associated cancers increased significantly in the U.S. from 2001 to 2017, according to a population-based study of trends presented during the virtual ASCO Annual Meeting. Read more.
American Cancer Society’s first female CEO discusses goals, lessons learned amid pandemic
Knudsen spoke with Healio about her goals as CEO of the American Cancer Society and its advocacy affiliate, the American Cancer Society Cancer Action Network, as well as her experience in improving patient care and care delivery systems. Read more.
Regular PSA screening may improve prostate cancer outcomes among younger Black men
Greater adherence to prostate-specific antigen screening reduced the risk for metastatic and lethal prostate cancer among Black men aged 40 years to 55 years, according to results of an observational study presented during the virtual ASCO Annual Meeting. Read more.
Treatment wih gene-edited cell therapies not associated with subsequent cancer risk
Patients with cancer who received genetically modified immune effector cells did not demonstrate an increased risk for developing subsequent malignancies, according to results of a retrospective study. Read more.
Gene therapy for sickle cell disease shows curative potential
Three patients with sickle cell disease who received the investigational gene therapy ARU-1801 (Aruvant Sciences) achieved and maintained normal hemoglobin levels, according to early results of a phase 1/phase 2 trial. Read more.